Lexicon Pharmaceuticals, Inc. insiders have been one-way buyers this past year: two people put roughly $2.7 million into the stock and nobody sold on the open market.
Biggest single buyer: Artal Group S.A., Director, with roughly $2 million.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. Big money check: 149 institutions held LXRX as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | DEBBANE RAYMOND | Director | Buy | 2,000 | $1.49 | $3K | SEC |
| Feb 25, 2026 | DEBBANE RAYMOND | Director | Buy | 100,000 | $1.47 | $147K | SEC |
| Feb 23, 2026 | DEBBANE RAYMOND | Director | Buy | 100,000 | $1.48 | $148K | SEC |
| Feb 23, 2026 | DEBBANE RAYMOND | Director | Buy | 50,000 | $1.44 | $72K | SEC |
| Feb 18, 2026 | DEBBANE RAYMOND | Director | Buy | 76,857 | $1.31 | $101K | SEC |
| Feb 18, 2026 | DEBBANE RAYMOND | Director | Buy | 57,952 | $1.31 | $76K | SEC |
| Feb 18, 2026 | DEBBANE RAYMOND | Director | Buy | 133,688 | $1.32 | $176K | SEC |
| Feb 4, 2026 | Artal Group S.A. | Director | Buy | 1,538,462 | $1.30 | $2.0M | SEC |
| Nov 17, 2023 | COATS LONNEL | CEO | Buy | 90,000 | $1.05 | $94K | SEC |
| Nov 14, 2023 | Amouyal Philippe | Director | Buy | 200,000 | $1.01 | $202K | SEC |
| Nov 13, 2023 | COATS LONNEL | CEO | Buy | 10,000 | $1.01 | $10K | SEC |
| Oct 12, 2023 | DEBBANE RAYMOND | Director | Buy | 148,820 | $1.03 | $153K | SEC |
| Oct 12, 2023 | DEBBANE RAYMOND | Director | Buy | 508,306 | $1.14 | $579K | SEC |
| Oct 12, 2023 | DEBBANE RAYMOND | Director | Buy | 342,874 | $1.08 | $370K | SEC |
| Sep 14, 2023 | WADE JEFFREY L | CFO | Buy | 10,000 | $1.38 | $14K | SEC |
In the last 12 months Lexicon Pharmaceuticals, Inc. insiders made open-market purchases worth about $2.7 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in LXRX was filed on 2026-02-27.
149 investment managers reported holding LXRX in SEC Form 13F filings for Q2 2026.
No congressional trades in LXRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).